Psychiatry Flashcards
Opioids
Intoxication: euphoria, respiratory and CNS depression, decreased gag reflex, pupillary constriction, seizures
Treatment: naloxone, naltrexone
Withdrawal: sweating, dilated pupils, lacrimation, piloerection, fever, rhinorrhea, yawning, nausea, stomach cramps, diarrhea
Treatment: long term suppport, mehodone, buprenoprhine
Benzodiazepines
Intoxification: greater safety margin. Ataxia, minor respiratory depression.
Treatment: supportive care, consider flumazenil
Withdrawal: sleep disturbance, depression, rebound anxiety, seizure, tachycardia palpitations, psychosis
Caffeine
Intoxication: Restlessness, increased diuresis, muscle twitching
Withdrawal: lack of concentration, headache
Nicotine
Intoxication: Restlessness
Withdrawal: irritability, anxiety, craving, increased appetite, dysphoria
CYP 450 inducer
Treatment: nicotine patch, gum, or lozenges
Buproprion/varenicline
Venlafaxine
SNRI
MOA: inhibit 5-HT and NE reuptake
Clinical: depression, generalized anxiety and panic disorders, fibromylagia, diabetic neuropathy, female stress incontinence
Depression WITH PAIN
Toxicity: increase BP, stimulant effects, sedation, nausea, vomiting, diarrhea, increased intraocular pressure
Withdrawal effects: flu, electric shocks
Methadone
MOA: LONG ACTING oral opiate, mu receptor agonist
Used for heroin detoxification to suppress withdrawal symptoms
Fluphenazine
MOA: block dopamine receptors (increase cAMP)
High potency
Can be given in bi-monthly injection
Clinical: Schizophrenia positive symptoms, psychosis, acute mania, AND HUNTINGTONS
Toxicity: EPS-acute dystonia (sustained muscle contractions), akathisia (restlessness-treat with Beta blockers), Parkinsonism (tremor rigidity, bradykinesia-treat with anticholinergics (benztropine or diphenyhydramine) , increased LFTs, seizures
galactorrhea
Neuroleptic malignant syndrome: rigidity, myoglobinuria, autonomic instability, hyperpyrexia,
Treat with dantrolene, D2 agonists (brmocriptine)
Tardive dyskinesia: sterotpic oral-facial movements, lip smacking, chroathetoid movements
Alcohol
Intoxication: emotional liability, slurred speech, ataxia, coma, blackouts,
Serum y-glutamyltransfersase-sensitive indicator of alcohol use
Lab AST value is 2x ALT value
Chronic: Down regulates GABA receptors, up regulates NMDA receptors
Withdrawal:
Mild-symptoms similar to other depressants
Severe alcohol withdrawal can cause autonomic hyperactivity (increased temp and RR, insomnia) and Delirum tremens
Seziures, tachycardia, palpitatons
First manifestation is the shakes (tremors)
Treatment for Delirum tremens: benzodiazepines
Marijuana (cannabinoid)
MOA: Active ingredient in THC which stimulates canniboid receptors CB1 and CB2
Intoxication: euphoria, paranoid delusions, perception of slowed time, slowed reflexes, impaired judgement, social withdrawal, increased appetite, dry mouth, conjunctival injection, rapid heart rate, hallucinatons, short term memory loss
Prescription: dronabinol uses as antiemetic in chemo and appetite stimulant in AIDS
Withdrawal: irritability, depression, insomnia, nausea, anorexia
Symptoms peak in 48 hours
detectable in urine for 4-10 days but up to 30
stored in lipophilic tissues
Naloxone + buprenorphine
MOA: partial agonist
Long acting with fewer withdrawal symptoms than methadone
Naloxone not active if taken orally
Quetiapine
Atypical antipsychotic
MOA: Dopamine and sertonin antagonist
Clinical: schizophrenia positive and negative symptoms
MDD, PTSD
Toxicity: Least likely extrapyramidal, less anticholinergic side effects than traditional antipsychotics
increase glucose, lipids, weight gain, orthostasis, esophageal dysmotility,
SEDATING, CATARACTS, PARKINSON’s
PCP (phencyclidine)
MOA: antagnozies NMDA receptors
Intoxication: belligerence, impulsivness, fever, psychomotor agitation, analgesia, vertical and horizontal nystagmus, tachycardia, homicidality, ataxia, psychosis, delirium, seizures
Death due to trauma
Treatment: benzodiazpeines, rapid-acting antipsychotic
Withdrawal: depression, anxiety, irritability, restlessness, anergia (lack of energy), distrubances of thought and sleep
Naltrexone
Long acting opioid antagnosist used for relapse prevention once detoxified
Haloperidol
MOA: block dopamine receptors (increase cAMP)
High potency
Clinical: Schizophrenia positive symptoms, psychosis, acute mania, acute psychosis, Tourette syndrome AND HUNTINGTONS
Toxicity: EPS-acute dystonia (sustained muscle contractions), akathisia (restlessness-treat with Beta blockers), Parkinsonism (tremor rigidity, bradykinesia-treat with anticholinergics (benztropine or diphenyhydramine) , increased LFTs, seizures
galactorrhea
Neuroleptic malignant syndrome: rigidity, myoglobinuria, autonomic instability, hyperpyrexia,
Treat with dantrolene, D2 agonists (brmocriptine)
Tardive dyskinesia: sterotpic oral-facial movements, lip smacking, chroathetoid movements
Thioridazine
MOA: block dopamine receptors (increase cAMP)
Low potency
Clinical: Schizophrenia positive symptoms, psychosis, acute mania, AND HUNTINGTONS
Toxicity: EPS-acute dystonia (sustained muscle contractions), akathisia (restlessness-treat with Beta blockers), Parkinsonism (tremor rigidity, bradykinesia-treat with anticholinergics (benztropine or diphenyhydramine) , increased LFTs, seizures
galactorrhea
Neuroleptic malignant syndrome: rigidity, myoglobinuria, autonomic instability, hyperpyrexia,
Treat with dantrolene, D2 agonists (brmocriptine)
Tardive dyskinesia: sterotpic oral-facial movements, lip smacking, chroathetoid movements
RETINAL DEPOSITS
Mirtazapine
Atypical antidepressant
MOA: alpha2 antagonist (increases release of NE and 5HT) and potent 5HT2 and 5HT3 receptor antagonist
Toxicity: sedation (insomnia patients), increased appetite, weight gain (elderly, cancer or anorexic patients), dry mouth, agranulocytosis
Use in elderly
NO sexual and little GI side effects!
Olanzapine
Atypical antipsychotic
MOA: Dopmain and sertonin antagonist
Clinical: Schizophrenia positive and negative symptoms
Bipolar disorder,
Toxicity: Fewer EPS and anticholinergic side effects than traditional antipsychotics
Orthostasis, esophageal dysmotility
Weight gain-increased lipids and LFTS
Fluoxetine (Prozac)
MOA:Serotonin reuptake inhibitors
Take 4-8 weeks to have an effect use BDZs temporarily
Used commonly due to low incidence of side effects which resolve with time, no food restrictions, much safer in overdose
CYP450 inhibitor
Longest half life-no need to taper
Safe in pregnancy and with children
Clinical: depression, generalized anxiety disorder, panic disorder, OCD, bulimia, social phobias, PTSD, IBS, migraines, autsim
Toxicity: Fewer side effects than TCAs
GI distress, sexual dysfunction, serotonin syndrome, nausea, diarrhea, anxiety, weight loss, insomnia (vivid dreams), headaches, restlessness, seizures (low risk)
can elevate levels of neuroleptics increasing side effects
Can cause weight loss
Watch with cough supprsesant for serotonin syndrome
Aripiprazole
Atypical antipsychotic
MOA: dopamine and serotonin antagonist, partial dopamine agonist
Clinical: schizophrenia positive and negative symptoms
Bipolar disorder, OCD, anxiety disorder, depression, mania, Tourette syndrome
Toxicity: fewer EPS and anticholinergic side effects than traditional antipsychotcs
incresaed glucose, lipids, weight, orthostatsis, esophageal dysmotility
SEIZURES, MANIA, AKATHESIA
Serotonin syndrome
Occurs with any drug that increases serotonin
Linezolid, TCAs, MAO inhibitors, SNRIs, triptans, tramadol, SSRIs
Symptoms: hyperthermia confusion, myoclonus, cardiovascular collapse, tachycardia, flushing, diarrhea, seizures, diaphoresis, rhabdomyolysis, renal failure, and death
Treatment: cyproheptadine (5HT Receptor antagonist) and stop medications
Modafinil
Non amphetamine stimulant
1st line for narcolepsy
CYP-450 inducer
Amphetamines
Intoxication: euphoria, grandiosity, pupillary dilation, prolonged wakefulness and attention, hypertension, tachycardia, anorexia, paranoia,fever, diaphroresis, choreiform movements, tooth decay
Severe: cardiac arrest, seizure
Withdrawal: anhedonia (can’t experience pleasure from activities), increased appetite, hypersomnolence, existential crisis (question life)
Buspirone
MOA: stimulates 5-HT receptors
Clinical: generalized anxiety disorder
Does not cause sedation, addiction or tolerance
Does not interact with alcohol-useful in abuse patients
Takes 1-2 weeks to take effect
Lithium
MOA: not established
Clinical: mood stabilizer for bipolar disorder, blocks relapse and acute manic events, SIADH, Alcohol dependency, aggression
Toxicity: tremor, sedation, edema, heart block, ataxia, delirium, hypothyroidism, polyuria, n/v, slurred speech, hyperreflexia, metal taste, weight gain, seizures
CAN CAUSE NEPHRONGENIC DIABETES INSIPIDUS
Ebstein anomaly and malformation of great vessels
Thiazide diuretics, ACE inhibitors and NSAIDS increase lithium levels
MNOP: movement (tremor), nephrogenic diabetes insipidus, hypOthyroidism, Pregnancy probs
Methylphenidate, dextroampheatmine, metamphetamine, phentermine
MOA: increase catecholamines at the synaptic cleft, especially NE and dopamine
Treat: ADHD, narcolepsy, appetite control
Buproprion
Atypical antidperessant
MOA: increase NE and dopamine by inhibiting presynpatic uptake
Clinical: atypical depression and smoking cessation, migraines, depression in bipolar, adult ADHD
Toxicity: stimulant effects (tacchycardia, insomnia), headache, nausea
DON’T USE IN PATIENTS WITH EATING DISORDERS, EPILEPSY, OR ALCOHOL ABUSE DUE TO INCREASE RISK OF SEIZURES and psychosis or on MAOI
No sexual side effects!!!
Trazodone
MOA: blocks 5Ht2 and alpha1 adrenergic receptors
Clinical: primarily insomnia, high doses needed for antidepressant
Toxicity: sedation, nausea, priapism (constant boner), postural hypotension, hepatotoxicity, dizziness, orthostatsis, cardiac arrhythmias
Ziprasidone
Atypical antipsychotic-
MOA: Dopamine and serotonin antagonist
Clinical: Schizophrenia positive and negative symptoms,
Bipolar disorder, OCD, anxiety disorder, depression, mania, Tourette syndrome
Toxicity: fewer EPS and anticholinergic side effects than traditional antipsychotics
May prolong QT interval should obtain ECGs
Less metabolic side effects
Akathisia
reslessnes and agiation
Treatment: B-Blocker
Cocaine
MOA: Blocks reuptake of monoamines
Intoxication: impaired judgement, pupillary dilation, hallucinations, paranoid ideations, angina, sudden cardiac death (coronary artery vasospasm), stroke, intracranial hemorrhage, seizures, sympathetic stimulation-tachycardia
Treatment: benzodiazepines
Withdrawal: hypersomonlence, malaise, severe psychological craving, depression/suicidality, increased appetite, psychomotor retardation, MI (increased demand and decreased perfusion)
Resperidone
Atypical antipsychotic
MOA: Dopamine and Serotonin antagonists
Fast acting
Clinical: Schizophrenia positive and negative symptoms
Bipolar disorder OCD, anxiety disorder, depression, mania, Tourette syndrome/tics
toxicity: fewer EPS and anticholinergic side effects than traditional antipsychotics (however most likely atypical antipsychotic to cause EPS)
Increases prolactin leading to lactation and gynecomastia
Decreases GnRH, LH and FSH causing irregular menstruation and fertility issues
Varenicline
MOA: reinforces effects of nicotine that lead to dependene through partial agonistic acitivity on a4B2 nicotinic acetylcholin recpetor in CNS
Decreases symptoms of withdrawal and attenuating rewards
Clozapine
Atypical antipsychotics
MOA: Dopamine and serotonin antagonist
Acts on D4 receptors
Clinical: schizophrenia positive and negative symptoms (treatment resistant Schizo)
Toxicity: NO EPS and anticholinergic side effects than traditional antipsychotics (least likely atypical antipsychotic to cause EPS)
weight gain
AGRANULOCYTOSIS-requires weekly WBC monitoring
Seizures
MYOCARDITIS
LSD (Lysergic Acid Diethylamide)
Intoxication: perceptual distortion (visual auditory), visual hallucinations, depersonalization, anxiety, paranoia, psychosis, possible flashback
Phenelzine
MOA: Increase levels of amine NTs-NE, 5HT, and dopamine
Takes 2 weeks to re synthesize MAO- watch for serotonin syndrome-wait two weeks to switch to (fluoxetine 5 weeks), 2 weeks to come off
Clinical: atypical depression, anxiety, hypochondriasis
Toxicity: hypertensive crisis (ingestion of tyramine-wine and cheese), CNS stimulation, edema, orthostasis, weight gain, sexual, headache
Treat with phentolamine
Contraindicated: SSRIs, TCAs, St. John’s wort, meperidine, and dextromehtorphan-prevents serotonin syndrome
Barbituates
intoxication: Low safety margin, marked respiratory depression
CYP450 Inducers
Treatment: symptom management-assist respiration, increase BP
Withdrawal: delirium, life threatening cardiovascular collapse
Electro convulsive therapy
Produced painless seizure in anesthetized patient
Treatment for major depressive disorder refractory to other treatments or pregnant women with depression
Or when immediate response is necessary (suicide)
Depression with psychotic features and Catatonia are also indications
AE: disorientation, temporary headache, and partial anterograde/retrograde amnesia fully resolving in 6 months